a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
19 Years to 65 Years (Adult)
Sexes Eligible for Study:
ABO-compatible renal transplant recipients
HIV(+) donor or recipients
history of malignancy other than skin cancer (except completely cured basal cell ca or squamous cell ca)
more than three-fold increase in AST or ALT level for 28 days